Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cardiac Marker Testing Market Size Forecast: How Big Could The Market Get By 2030?
The cardiac marker testing market has experienced substantial expansion in recent years. It is projected to expand from $7.19 billion in 2025 to $7.93 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this growth can be ascribed to factors such as the restricted availability of high-sensitivity cardiac marker tests, dependence on centralized laboratory testing, the rising occurrence of cardiovascular diseases, heightened awareness among healthcare providers, and traditional manual diagnostic methods.
The cardiac marker testing market size is poised for substantial growth over the next few years, with projections indicating it will reach $11.61 billion in 2030, advancing at a compound annual growth rate (CAGR) of 10.0%. This anticipated expansion during the forecast period stems from factors such as the development of automated and portable cardiac marker testing devices, increasing adoption of point-of-care diagnostics, integration with digital health platforms, an expanding geriatric population coupled with cardiovascular risk, and enhancements in reagent and kit sensitivity. Prominent trends for this period include a rising uptake of high-sensitivity cardiac biomarker tests, the expansion of point-of-care testing facilities, the integration of automated analyzers and immunoassay systems, a growing application of cardiac marker testing in preventive cardiology, and increasing demand for portable diagnostic devices.
Get A Free Sample Report With In-Depth Market Insights:
Cardiac Marker Testing Market Growth Factors Behind Sustained Expansion
The expanding prevalence of cardiovascular diseases is anticipated to propel the growth of the cardiac marker testing market moving forward. These conditions, known as CVDs, represent a collection of disorders impacting the heart and blood vessels, including issues like coronary artery disease, heart failure, and stroke. The escalating number of cardiovascular disease cases is attributed to factors such as an unhealthy diet, insufficient physical activity, tobacco use, excessive alcohol consumption, and air pollution. Cardiac marker testing is crucial for cardiovascular diseases to accurately diagnose, evaluate the seriousness, and track the progression or response to therapy for heart conditions by identifying particular biomarkers released during myocardial injury. For instance, in January 2024, data from the American Heart Association, a US-based nonprofit organization, indicated that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000, representing a 4.0% rise from 224.4 per 100,000 when measured against 2023. Thus, the increasing occurrence of cardiovascular diseases drives the cardiac marker testing market.
Cardiac Marker Testing Market Segmentation And Category Overview
The cardiac marker testing market covered in this report is segmented –
1) By Product: Reagents And Kits, Instruments
2) By Biomarker Type: Troponin I And T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein, Other Biomarker Types
3) By Application: Laboratory Testing Facilities, Point-Of-Care Testing Facilities, Academic Institutions
Subsegments:
1) By Reagents and Kits: Troponin Test Kits, B-type Natriuretic Peptide (BNP) Test Kits, Creatine Kinase-MB (CK-MB) Test Kits, Myoglobin Test Kits, Other Cardiac Biomarker Reagents
2) By Instruments: Point-Of-Care Testing Devices, Automated Analyzers, Immunoassay Systems, Portable Diagnostic Devices
Cardiac Marker Testing Market Industry Trends Fueling Future Revenue Growth
Leading companies within the cardiac marker testing market are concentrating on developing technologically advanced products, such as cardiac assays, to provide valuable, precise information about heart health and function. Cardiac assays are diagnostic examinations engineered to measure biomarkers or other indicators within blood or other samples to assess heart function, diagnose cardiovascular diseases, or evaluate the risk of heart-related conditions. For instance, in October 2023, Mindray, a China-based medical device company, launched the troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTnI assay distinguishes itself with exceptional sensitivity, precision, and reliability, surpassing minimum requirements by achieving a 93% detection rate between the limit of detection (LoD) and the 99th percentile upper reference limit (URL) and maintaining an imprecision coefficient of variation (CV) below 5% at the 99th URL, making it highly effective in detecting myocardial injury. Mindray’s NT-proBNP assay is an important cardiac marker for heart failure, showing high precision with a coefficient of variation (CV) of <=5%. It also effectively minimizes interference from 55 common heart disease medications, ensuring accurate detection and management of heart failure.
Cardiac Marker Testing Market Top Companies Driving Competitive Growth
Major companies operating in the cardiac marker testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Tosoh Corporation, Guangzhou Wondfo Biotech Co. Ltd., Randox Laboratories Ltd., Getein Biotech Inc., Fujirebio Inc., Mayo Clinic Laboratories, Alere Inc., Nano-Ditech Corporation, Ortho Clinical Diagnostics, QuidelOrtho Corporation, DiaSorin S.p.A., PerkinElmer Inc., Meso Scale Diagnostics LLC, Boditech Med Inc., Response Biomedical Corp.
View The Full Cardiac Marker Testing Market Report:
Cardiac Marker Testing Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the cardiac marker testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
